A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages

Sadeghi, Hanieh; Kamal, Aryan; Ahmadi, M. Amir; Najafi, Hadi; Sharifi-Zarchi, Ali; Haddad, Peyman; Shayestehpour, Bahareh; Kamkar, L.; Salamati, Masoumeh; Geranpayeh, Loabat; Lashkari, Marzieh; Totonchi, Mehdi

doi:10.1080/15476286.2021.1989218

Cited by 6 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 16 142 articles were identified in the aforementioned databases (Table 1). However, 234 articles were retained for full reading, following the elimination of duplicates and articles whose title and abstract did not meet the eligibility criteria; of these, only 136 12…”

Section: Resultsmentioning

confidence: 99%

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common neoplasm in women worldwide. Liquid biopsy (LB) is a non-invasive diagnostic technique that allows the analysis of biomarkers in different body fluids, particularly in peripheral blood and also in urine, saliva, nipple discharge, volatile respiratory fluids, nasal secretions, breast milk, and tears. The objective was to analyze the available evidence related to the use of biomarkers obtained by LB for the early diagnosis of BC. Methods: Articles related to the use of biomarkers for the early diagnosis of BC due to LB, published between 2010 and 2022, from the databases (WoS, EMBASE, PubMed, and SCOPUS) were included. The MInCir diagnostic scale was applied in the articles to determine their methodological quality (MQ). Descriptive statistics were used, as well as determination of weighted averages of each variable, to analyze the extracted data. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) are described. Results: In this systematic review (SR), 136 articles met the selection criteria, representing 17 709 patients with BC. However, 95.6% were case-control studies. In 96.3% of cases, LB was performed in peripheral blood samples. Most of the articles were based on microRNA (miRNA) analysis. The mean MQ score was 25/45 points. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) have been found. Conclusions: The determination of biomarkers through LB is a useful mechanism for the diagnosis of BC. The analysis of miRNA in peripheral blood is the most studied methodology. Our results indicate that LB has a high sensitivity and specificity for the diagnosis of BC, especially in early stages.

show abstract

Section: Resultsmentioning

confidence: 99%

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

show abstract

“…The expression profile of single miRs does not have a stable diagnostic potential for BC [27]. The use of miR-181a and miR-25 as markers seems possible only within the framework of a large diagnostic panel, which may include miR-181a and miR-25, as well as their target genes.…”

Section: Discussionmentioning

confidence: 99%

Serum miR-181a and miR-25 in patients with malignant and benign breast diseases

Perepechaeva,

Studenikina,

Grishanova

et al. 2023

BIOMED KHIM

View full text Add to dashboard Cite

Breast tumor diseases include a wide range of pathologies that require different approaches to their treatment. MicroRNA (miR) levels, reflecting regulation of the gene expression involved in tumorigenesis, can be diagnostic and prognostic markers of breast diseases. The levels of circulating miR-181a and miR-25 were measured in patients with benign breast diseases (BBD), patients with invasive carcinoma of a nonspecific type (ICNT) and also in conditionally healthy women. Expression of both miRs was higher in patients of both groups as compared to controls; at the same time, the content of serum miR-181a and miR-25 was higher in BBD patients than in ICNT patients. The detected changes may be of interest in the context of precancerous changes in BBD. It seems possible to use them in the future as markers of the pathological process as a part of a large diagnostic panel.

show abstract

“…When the AUC is close to one, the diagnostic value of miRNA is higher as there are substantial differences between BC and negative control samples. Additionally, while assessing the miRNA diagnostic potential, sensitivity, and specificity that indicate the accuracy of biomarkers also need to be considered ( 115 , 116 ). E.g., a study revealed that four plasma miRNA panel comprising miR-24, miR-206, miR-373, and miR-1246 could discriminate BC patients from healthy subjects with 96% specificity, 98% sensitivity, and 97% accuracy ( 117 , 118 ) while the combination of miR-142-5p and miR-320a could distinguish luminal A subtype from healthy individuals with 100% sensitivity, 93.80% specificity, and AUC 0.94 ( 117 ).…”

Section: Diagnostic and Prognostic Function Of Mirnas In Breast Cancermentioning

confidence: 99%

Potential utility of miRNAs for liquid biopsy in breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer (BC) remains the most prevalent malignancy due to its incidence rate, recurrence, and metastasis in women. Conventional strategies of cancer detection– mammography and tissue biopsy lack the capacity to detect the complete cancer genomic landscape. Besides, they often give false- positive or negative results. The presence of this and other disadvantages such as invasiveness, high-cost, and side effects necessitates developing new strategies to overcome the BC burden. Liquid biopsy (LB) has been brought to the fore owing to its early detection, screening, prognosis, simplicity of the technique, and efficient monitoring. Remarkably, microRNAs (miRNAs)– gene expression regulators seem to play a major role as biomarkers detected in the samples of LB. Particularly, miR-21 and miR-155 among other possible candidates seem to serve as favorable biomarkers in the diagnosis and prognosis of BC. Hence, this review will assess the potential utility of miRNAs as biomarkers and will highlight certain promising candidates for the LB approach in the diagnosis and management of BC that may optimize the patient outcome.

show abstract

A novel panel of blood-based microRNAs capable of discrimination between benign breast disease and breast cancer at early stages

Cited by 6 publications

References 51 publications

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Serum miR-181a and miR-25 in patients with malignant and benign breast diseases

Potential utility of miRNAs for liquid biopsy in breast cancer

Contact Info

Product

Resources

About